Keyphrases
Tumor
100%
Immune Checkpoint Inhibitors
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Immune Checkpoint Inhibitor Monotherapy
100%
Programmed Death-ligand 1 Expression
100%
Non-squamous
66%
Cox Proportional Hazards Model
66%
Squamous Cell
66%
Liver Metastasis
33%
Patient Characteristics
33%
Retrospective Analysis
33%
Progression-free
33%
Survival Duration
33%
Neutrophil-lymphocyte Ratio
33%
Medicine and Dentistry
Neoplasm
100%
Immune Checkpoint Inhibitor
100%
Non Small Cell Lung Cancer
100%
Programmed Death 1 Ligand 1
100%
Monotherapy
75%
Proportional Hazards Model
50%
Squamous Cell
50%
Liver Metastasis
25%
Patient Characteristics
25%
Progression Free Survival
25%
Lymphocyte
25%
Neutrophil
25%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Immune Checkpoint Inhibitor
100%
Non Small Cell Lung Cancer
100%
Programmed Death 1 Ligand 1
100%
Monotherapy
75%
Liver Metastasis
25%
Progression Free Survival
25%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Progression Free Survival
25%
Lymphocyte
25%